Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Neuroprotective effects of riluzole in neurotrauma models: a review.
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
Raltegravir (Isentress) pilot study in relapsing multiple sclerosis (INSPIRE)
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
mfERG_LAB: Software for processing multifocal electroretinography signals.
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Solodyn
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells.
No Regional Gray Matter Atrophy Differences between Pediatric- and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
Submembranous cytoskeletons stabilize nodes of Ranvier.
Tocilizumab, MS, and NMOSD.
[Vitamin D for prevention of diseases?].
No association between chronic cerebrospinal venous insufficiency and pediatric-onset multiple sclerosis.
ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients
Longitudinally extensive transverse myelitis with anti-NMDA receptor antibodies during a systemic lupus erythematosus flare-up.
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.

Pages